pCPA Activity Overview
Status | Total Negotiations | Summary |
---|---|---|
Active Negotiations | 40 | Non-oncology: 27 Oncology: 13 |
Under Consideration for Negotiation | 18 | Non-oncology: 10 Oncology: 8 |
Completed Negotiations | 840 | With Letter of Intent: 730 Without agreement: 110 |
Negotiations That Were Not Pursued | 111 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
Brand Name | Manufacturer | Indication | Engagement Date |
---|---|---|---|
Opdivo SC | Bristol Myers Squibb Canada Inc. | Multiple Indications | |
Methofill | Accord Healthcare Inc. | Multiple Indications | |
Nordimet | Nordic Pharma | Multiple Indications | |
Skyclarys | Biogen Canada Inc. | Friedreich’s ataxia | |
Ferinject | CSL Vifor | Iron Deficiency Anemia | |
Ferinject | CSL Vifor | Iron deficiency in adult patients with heart failure | |
Iqirvo | Ipsen Biopharmaceuticals Canada, Inc. | Primary biliary cholangitis | |
Sogroya | Novo Nordisk Canada Inc. | Growth hormone deficiency | |
Omnipod 5 | Insulet Canada Corporation | Patients with Type 1 Diabetes aged 2 years and old | |
Camcevi | Accord Healthcare Inc. | For the treatment of adult patients with advanced prostate cancer |